{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:24:46Z","timestamp":1761611086758},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6460,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1093\/annonc\/mdf063","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:59:57Z","timestamp":1027724397000},"page":"721-729","source":"Crossref","is-referenced-by-count":59,"title":["Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival"],"prefix":"10.1016","volume":"13","author":[{"given":"T.","family":"Conroy","sequence":"first","affiliation":[]},{"given":"P.-L.","family":"Etienne","sequence":"additional","affiliation":[]},{"given":"A.","family":"Adenis","sequence":"additional","affiliation":[]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[]},{"given":"B.","family":"Paillot","sequence":"additional","affiliation":[]},{"given":"J.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"J.-F.","family":"Seitz","sequence":"additional","affiliation":[]},{"given":"E.","family":"Francois","sequence":"additional","affiliation":[]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[]},{"given":"D.J.T.","family":"Wagener","sequence":"additional","affiliation":[]},{"given":"F.","family":"Kohser","sequence":"additional","affiliation":[]},{"given":"S.","family":"Daamen","sequence":"additional","affiliation":[]},{"given":"M.","family":"Praet","sequence":"additional","affiliation":[]},{"given":"T.","family":"Gorlia","sequence":"additional","affiliation":[]},{"given":"B.","family":"Baron","sequence":"additional","affiliation":[]},{"given":"J.","family":"Wils","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf063_bb0010","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0959-8049(98)00329-3","article-title":"Survival of patients with oesophageal and gastric cancers in Europe","volume":"34","author":"Faivre","year":"1998","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdf063_bb0015","first-page":"2","article-title":"The changing epidemiology of esophageal cancer","volume":"26","author":"Blot","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/bjs.1800770804","article-title":"Surgical therapy of oesophageal carcinoma","volume":"77","author":"Muller","year":"1990","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdf063_bb0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1200\/JCO.1997.15.1.277","article-title":"Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an Intergroup Study","volume":"15","author":"Al-Sarraf","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdf063_bb0030","first-page":"12","article-title":"Chemotherapy in esophageal cancer","volume":"26","author":"Enzinger","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0035","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","article-title":"Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer","volume":"33","author":"Bleiberg","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf063_bb0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.1996.14.1.164","article-title":"Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma","volume":"14","author":"Conroy","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0045","first-page":"1247","article-title":"Vinorelbine plus cisplatinum for the treatment of stage IIIb and IV non-small cell lung cancer","volume":"14","author":"Gebbia","year":"1994","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdf063_bb0050","series-title":"WHO Handbook for Reporting Results of Cancer Treatment","article-title":"World Health Organisation","year":"1979"},{"key":"10.1093\/annonc\/mdf063_bb0055","doi-asserted-by":"crossref","unstructured":"Hermanek P, Sobin HL. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. Berlin: Springer-Verlag 1987.","DOI":"10.1007\/978-3-642-82982-6"},{"key":"10.1093\/annonc\/mdf063_bb0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdf063_bb0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf063_bb0070","first-page":"119","article-title":"Tumor eligibility and response criteria for phase II and III studies and (sub) acute toxicity grading with suggested amendments to WHO criteria","author":"Van Oosterom","year":"1992","journal-title":"In EORTC Data Center Procedures Manual 2nd edition EORTC"},{"key":"10.1093\/annonc\/mdf063_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdf063_bb0080","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0016-5085(91)70017-R","article-title":"A prospective comparison of laser therapy and intubation in endoscopic palliation for malignant dysphagia","volume":"100","author":"Loizou","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdf063_bb0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdf063_bb0090","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"1995"},{"key":"10.1093\/annonc\/mdf063_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdf063_bb0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality of life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0105","article-title":"EORTC. QLQ-C30 Reference Values. Brussels: EORTC Quality of Life Study","author":"Fayers","year":"1998","journal-title":"Group"},{"key":"10.1093\/annonc\/mdf063_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdf063_bb0115","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","article-title":"Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus","volume":"86","author":"Ajani","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdf063_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1006390216220","article-title":"A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group","volume":"18","author":"Macdonald","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdf063_bb0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/028418699431690","article-title":"Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma","volume":"38","author":"Warner","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/110241598750005273","article-title":"5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial","volume":"164","author":"Levard","year":"1998","journal-title":"Eur J Surg"},{"key":"10.1093\/annonc\/mdf063_bb0135","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1200\/JCO.1998.16.5.1826","article-title":"Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus","volume":"16","author":"Ilson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0140","first-page":"316","article-title":"A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus","volume":"6","author":"Ilson","year":"2000","journal-title":"Cancer J"},{"key":"10.1093\/annonc\/mdf063_bb0145","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1999.17.10.3270","article-title":"Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer","volume":"17","author":"Ilson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1998.524","article-title":"Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer","volume":"78","author":"Petrasch","year":"1998","journal-title":"Br J Cancer"},{"issue":"Abstr 1266","key":"10.1093\/annonc\/mdf063_bb0155","first-page":"320a","article-title":"A phase II multi-center trial of paclitaxel (P) (Taxol) as a weekly one-hour infusion in advanced esophageal cancer (EC)","volume":"19","author":"Kelsen","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 1151","key":"10.1093\/annonc\/mdf063_bb0160","first-page":"300a","article-title":"A phase II study of docetaxel in advanced, inoperable squamous carcinoma of the esophagus","volume":"18","author":"Slabber","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0165","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/oxfordjournals.annonc.a059095","article-title":"Treatment of recurrent and\/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial","volume":"6","author":"Gebbia","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf063_bb0170","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1394::AID-CNCR17>3.0.CO;2-V","article-title":"Vinorelbine, cisplatin and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous carcinoma of the head and neck: results of a phase II multicenter study","volume":"79","author":"Gebbia","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf063_bb0175","first-page":"231","article-title":"Phase II study of 5-fluorouracil (5-FU) cisplatin (CDDP) and vinorelbine (VNR) in patients (pts) with advanced adenocarcinoma of oesophagus","author":"Vicent","year":"1999","journal-title":"Proceedings of the 9th International Congress on Anti-cancer Treatment Paris France"},{"key":"10.1093\/annonc\/mdf063_bb0180","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/0277-5379(91)90460-U","article-title":"Severe mucositis after chemotherapy with vinorelbine, 5-fluorouracil, leucovorin and cisplatin","volume":"27","author":"Monnet","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf063_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0959-8049(96)00412-1","article-title":"Quality of life assessment in clinical trials\u2014guidelines and a checklist for protocol writers: the UK Medical Research Council Experience","volume":"33","author":"Fayers","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf063_bb0190","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D","article-title":"Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma. Response, toxicity, quality of life and survival","volume":"77","author":"Bamias","year":"1996","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf063_bb0195","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/0959-8049(96)00199-2","article-title":"Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer","volume":"32A","author":"Blazeby","year":"1996","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/5\/721\/529834\/mdf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:31:21Z","timestamp":1582183881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419628796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S0923753419628796"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf063","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}